SONN (Sonnet BioTherapeutics Holdings) LT-Debt-to-Total-Asset: 0.00 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SONN Sonnet BioTherapeutics Holdings Inc SONN
28 GF Score
Price $1.26
View Full Analysis

What is Sonnet BioTherapeutics Holdings LT-Debt-to-Total-Asset?

Sonnet BioTherapeutics Holdings SONN 28 LT-Debt-to-Total-Asset is 0.00 as of Jun. 2025. GuruFocus rates SONN with a GF Score™ of 28/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sonnet BioTherapeutics Holdings's long-term debt to total assests ratio for the quarter that ended in Jun. 2025 was 0.00.

Sonnet BioTherapeutics Holdings's long-term debt to total assets ratio declined from Jun. 2024 (0.01) to Jun. 2025 (0.00). It may suggest that Sonnet BioTherapeutics Holdings is progressively becoming less dependent on debt to grow their business.

Sonnet BioTherapeutics Holdings  (NAS:SONN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sonnet BioTherapeutics Holdings LT-Debt-to-Total-Asset Related Terms

Sonnet BioTherapeutics Holdings LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Sonnet BioTherapeutics Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sonnet BioTherapeutics Holdings LT-Debt-to-Total-Asset Chart

Sonnet BioTherapeutics Holdings Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.03 0.00 0.04 0.02 0.02

Sonnet BioTherapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.00 0.00 0.00
SONN
28GF Score
Sonnet BioTherapeutics Holdings Inc SONN
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sonnet BioTherapeutics Holdings LT-Debt-to-Total-Asset Calculation

Sonnet BioTherapeutics Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (A: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Sep. 2024 )/Total Assets (A: Sep. 2024 )
=0.047/2.771
=0.02

Sonnet BioTherapeutics Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (Q: Jun. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2025 )/Total Assets (Q: Jun. 2025 )
=0/2.055
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Sonnet BioTherapeutics Holdings (SONN) has a LT-Debt-to-Total-Asset of 0.00 as of Jun. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sonnet BioTherapeutics Holdings and its competitors.
Is Sonnet BioTherapeutics Holdings' LT-Debt-to-Total-Asset too high?
Sonnet BioTherapeutics Holdings' current LT-Debt-to-Total-Asset is 0.00. Overall, Sonnet BioTherapeutics Holdings has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Sonnet BioTherapeutics Holdings' LT-Debt-to-Total-Asset compare to CING and BOLD?
Sonnet BioTherapeutics Holdings' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sonnet BioTherapeutics Holdings and its competitors. Sonnet BioTherapeutics Holdings's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonnet BioTherapeutics Holdings stock overvalued right now?
Sonnet BioTherapeutics Holdings (SONN) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Sonnet BioTherapeutics Holdings' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Sonnet BioTherapeutics Holdings (SONN), the current LT-Debt-to-Total-Asset is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sonnet BioTherapeutics Holdings Business Description

Address 100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
28GF Score

Get the complete analysis for SONN

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price